**Supplementary Materials**

**Table S1**: Search terms for the systematic review and meta-analysis

|  |  |  |
| --- | --- | --- |
| ***OR*** | ***AND*** | ***OR*** |
| Dequalinium Chloride (Text) | Bacterial vaginosis (Text) |
| Dequaliniumchloride (Text) | Vaginosis, bacterial (MeSH) |
| Dequalinium (MeSH) | Candidiasis, vulvovaginal (MeSH) |
| Fluomizin (Text) | Vaginal Candidosis (Text) |
| Anti-infective agents, local (MeSH) | Vaginal Candidiasis (Text) |
| Local Anti-infective agents (Text) | Vulvovaginal Candidosis (Text) |
| Vaginal antiseptic (Text) | Vulvovaginal Candidiasis (Text) |
|  | Vaginal Infection (Text) |

**Table S2**: Characteristics of the two studies on bacterial vaginosis included in the meta-analysis

|  |  |  |
| --- | --- | --- |
|  | **Petersen et al.[2]** | **Weissenbacher et al.[25]** |
| **Participants** | 73 | 321 |
| **Study Group**  | 36  | 135 |
| **Drop-out Rate** | 25% | 18% |
| **Mean Age**  | 35.5  | n/a (Median: 32) |
| **Cure Rate** | 75% | 79.5% |
| **Adverse Events** | n/a | 134 |
| **Control Group**  | 20  | 116 |
| **Drop-out Rate** | 20% | 26% |
| **Mean Age** | 34.8  | n/a (Median 31)  |
| **Cure Rate** | 75% | 77.6% |
| **Adverse Events** | n/a | 163 |

*n/a = not applicable, Age in years*

**Table S3**: Characteristics of the two included studies on vulvovaginal candidiasis for meta-analysis

|  |  |  |
| --- | --- | --- |
|  | **Petersen et al.[2]** | **Thamkantho et al.[24]** |
| **Participants** | 35 | 150 |
| **Test Group**  | 19 | 66 |
| **Drop-out Rate** | 17% | 11% |
| **Mean Age** | 35.5  | 32.1  |
| **Cure Rate** | 84.2% | 84.9% |
| **Adverse Events** | n/a | 0 |
| **Control Group**  | 9 | 74 |
| **Drop-out Rate** | 25% | 3% |
| **Mean Age** | 34.8  | 29.8  |
| **Cure Rate** | 88.9% | 85.1% |
| **Adverse Events** | n/a | 0 |

*n/a = not applicable, Age in years*